Thank you for your deep commitment in treating your patients with immune-mediated-inflammatory diseases. We recognize the arrival of COVID-19 has brought many challenges in your clinical practice and we want to acknowledge the impact you have on your patients' lives.
Questions about COVID-19?
For information about what AbbVie is doing to address the global COVID-19 crisis, please click here
AbbVie has not studied the use of SKYRIZI in patients with COVID-19.
At this time, the safety and efficacy of the authorized COVID-19 vaccines have not been established in immunocompromised persons, persons with autoimmune conditions or persons who take immunosuppressive medications or therapies1 such as SKYRIZI.
Each patient’s unique clinical circumstances should be considered when managing their SKYRIZI therapy and when deciding if a vaccine is appropriate for them.
Select Information about Infections and Immunizations from the Prescribing Information2
SKYRIZI may increase the risk of infection. Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until the infection resolves.
Prior to initiating therapy with SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI. No data are available on the response to live or inactive vaccines.
Please see additional Important Safety Information for SKYRIZI below.
Please refer to the full SKYRIZI Prescribing Information for additional information.
Due to the rapidly evolving situation, interim guidance disseminated by government public health agencies and Dermatology professional medical societies such as the International Psoriasis Council and National Psoriasis Foundation on disease management and COVID-19, including authorized vaccines, is being updated frequently and should be checked often.
References: 1. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Accessed January 6, 2021. 2. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Important Safety Information
SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.
In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.
Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
Administration of Vaccines
Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.
Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.
Please see Full Prescribing Information.